Juno Therapeutics Inc. (JUNO)

86.96
0.09 0.10
Prev Close 86.87
Open 86.97
Day Low/High 86.90 / 87.01
52 Wk Low/High 19.62 / 87.01
Volume 3.70M
Avg Volume 4.51M
Exchange
Shares Outstanding 116.11M
Market Cap 10.10B
EPS -4.10
Div & Yield N.A. (N.A)
Here's a Reason Why Juno Therapeutics (JUNO) Stock Is Surging Today

Here's a Reason Why Juno Therapeutics (JUNO) Stock Is Surging Today

Juno Therapeutics (JUNO) stock was higher on Tuesday after Kite Pharma (KITE) released positive data from a lymphoma drug trial.

Kite Pharma Claims CAR-T Trial Victory, FDA Filing Next

Kite Pharma Claims CAR-T Trial Victory, FDA Filing Next

Kite Pharma's CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with an aggressive form of lymphoma, the company said Tuesday.

Has Juno Finally Beached Its Downtrend?

Has Juno Finally Beached Its Downtrend?

Juno Therapeutics' chart, and fortune, is on the rise.

The Law Offices Of Howard G. Smith Announces An Expanded Class Period In The Securities Class Action On Behalf Of Juno Therapeutics, Inc. Investors

The Law Offices Of Howard G. Smith Announces An Expanded Class Period In The Securities Class Action On Behalf Of Juno Therapeutics, Inc. Investors

Law Offices of Howard G. Smith announces that a new class action lawsuit has been filed on behalf of investors who purchased Juno Therapeutics, Inc.

CORRECTING and REPLACING JCAR014 Clinical Data Published in Science Translational Medicine: Patients with Advanced Lymphoma in Remission after T-cell Therapy

CORRECTING and REPLACING JCAR014 Clinical Data Published in Science Translational Medicine: Patients with Advanced Lymphoma in Remission after T-cell Therapy

In the contact information of the release, the email address for Christopher Williams should read: chris.

September 12th Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of Deadline In The Class Action Lawsuit Against Juno Therapeutics, Inc.

September 12th Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of Deadline In The Class Action Lawsuit Against Juno Therapeutics, Inc.

Law Offices of Howard G. Smith reminds investors of the upcoming  September 12, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the "Class") of investors who purchased...

Juno Therapeutics To Present At September 2016 Investor Conferences

Juno Therapeutics To Present At September 2016 Investor Conferences

Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced that it will webcast its presentations at two investor conferences in September.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAN, ABDC, APO, IRCP, LIVE, LVS, ST, TOF Downgrades: CPB, LENS, LILA, PAY, PDCO, RRD, TATT Initiations: CRBP, JUNO Read on to get TheStreet Quant Ratings' detailed report:

Kessler Topaz Meltzer & Check, LLP Reminds Juno Therapeutics, Inc. Investors Of Deadline

Kessler Topaz Meltzer & Check, LLP Reminds Juno Therapeutics, Inc. Investors Of Deadline

Kessler Topaz Meltzer & Check, LLP reminds Juno Therapeutics, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Juno Therapeutics Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 12, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Juno Therapeutics Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 12, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Juno Therapeutics Inc.

JUNO INVESTORS NOTICE: Lieff Cabraser Reminds Investors Of Securities Class Action Against Juno Therapeutics, Inc.

JUNO INVESTORS NOTICE: Lieff Cabraser Reminds Investors Of Securities Class Action Against Juno Therapeutics, Inc.

The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in securities class litigation brought on behalf of investors who purchased or...

JUNO INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Juno Therapeutics Inc. And A Lead Plaintiff Deadline Of September 12, 2016

JUNO INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Juno Therapeutics Inc. And A Lead Plaintiff Deadline Of September 12, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington, Seattle Division on behalf of investors who purchased Juno Therapeutics Inc.

Brower Piven Alerts Shareholders Of Upcoming Deadline In Class Action Lawsuit And Encourages Those With Substantial Losses From Investment In Juno Therapeutics, Inc. To Contact The Firm

Brower Piven Alerts Shareholders Of Upcoming Deadline In Class Action Lawsuit And Encourages Those With Substantial Losses From Investment In Juno Therapeutics, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf...

SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Juno Therapeutics, Inc.

SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Juno Therapeutics, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Juno Therapeutics, Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Juno Therapeutics Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 12, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Juno Therapeutics Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 12, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Juno Therapeutics Inc.

JUNO INVESTORS ALERT: Lieff Cabraser Reminds Investors Of Securities Class Action Against Juno Therapeutics, Inc.

JUNO INVESTORS ALERT: Lieff Cabraser Reminds Investors Of Securities Class Action Against Juno Therapeutics, Inc.

The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in securities class litigation brought on behalf of investors who purchased...

JUNO INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Juno Therapeutics Inc. And A Lead Plaintiff Deadline Of September 12, 2016

JUNO INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Juno Therapeutics Inc. And A Lead Plaintiff Deadline Of September 12, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington, Seattle Division on behalf of investors who purchased Juno Therapeutics Inc.

Juno Therapeutics Reports Second Quarter 2016 Financial Results

Juno Therapeutics Reports Second Quarter 2016 Financial Results

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today reported financial results and business highlights for the...

Juno Therapeutics Announces Multiple Myeloma Partnership With Memorial Sloan Kettering Cancer Center And Eureka Therapeutics For Developing CAR T Cell Immunotherapy Against Multiple Novel Targets

Juno Therapeutics Announces Multiple Myeloma Partnership With Memorial Sloan Kettering Cancer Center And Eureka Therapeutics For Developing CAR T Cell Immunotherapy Against Multiple Novel Targets

Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced today that it has entered into an exclusive license...

Juno Therapeutics To Report Second Quarter 2016 Financial Results On Thursday, August 4

Juno Therapeutics To Report Second Quarter 2016 Financial Results On Thursday, August 4

Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the second quarter 2016 on Thursday, August 4, 2016, after the close of U.

JUNO INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Juno Therapeutics, Inc.

JUNO INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Juno Therapeutics, Inc.

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased or otherwise acquired the securities of Juno Therapeutics, Inc.

INVESTOR ALERT: Brower Piven Notifies Shareholders Of Securities Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Juno Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline

INVESTOR ALERT: Brower Piven Notifies Shareholders Of Securities Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Juno Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf...

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Juno Therapeutics Inc. And Reminds Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Juno Therapeutics Inc. And Reminds Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces that a class action lawsuit has been filed against Juno Therapeutics Inc.

'Mad Money' Lightning Round: Take Bristol-Myers Over Juno

'Mad Money' Lightning Round: Take Bristol-Myers Over Juno

Cramer says Abiomed is too expensive while Harman was hurt by the strong dollar.

Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail

Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail

Johnson & Johnson was easy, Cramer says, but other stocks were more problematic.

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.

IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Juno Therapeutics Inc. And Reminds Investors With Losses To Contact The Firm

IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Juno Therapeutics Inc. And Reminds Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces that a class action lawsuit has been filed against Juno Therapeutics Inc.